Neuland Laboratories Accelerates Commercial Peptide Capacity Expansion Following Strong Revenue Growth
Neuland Laboratories Ltd 路 Press Release 路 15 Sept 2026, 3:57 pm
Neuland Laboratories Accelerates Commercial Peptide Capacity Expansion Following Strong Revenue Growth Neuland Laboratories operationalized the first of four commercial peptide modules on 15th Sep'26, investing $30 million to add 7,000 L total reactor capacity (750 L SPPS, 6,250 L LPPS). Work on module two is advancing ahead of schedule, targeting up to 18,000 L capacity to capture expanding demand across obesity, metabolic, and oncology pipelines. Supported by 212 peptide specialists, this expansion follows a 116% YoY surge in Neuland鈥檚 latest quarterly revenues, driven by rising commercial contracts and clinical-stage projects.
Original exchange filing (PDF)
More announcements from Neuland Laboratories Ltd
- Intimation about Schedule of Analyst / Institutional Investor Meeting on November 17, 2026 路 06 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) 路 05 Nov 2026
- Audio Recording of the Earnings call conducted on November 3, 2026 路 04 Nov 2026
- Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Press Release on the Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Disclosure under Regulation 30 of SEBI Listing Regulations 路 03 Nov 2026
- Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 03 Nov 2026
